Cargando…

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials

Recent major phase III trials led to the approval of immune checkpoint inhibitors (ipilimumab, pembrolizumab, and nivolumab) in metastatic malignant melanoma (MM). We aim to assess whether median progression-free survival, and 1 and 2-year overall survival (OS) rates are reliable surrogate endpoints...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petrelli, Fausto, Coinu, Andrea, Cabiddu, Mary, Borgonovo, Karen, Ghilardi, Mara, Lonati, Veronica, Barni, Sandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937921/ https://www.ncbi.nlm.nih.gov/pubmed/27368007 http://dx.doi.org/10.1097/MD.0000000000003997

Ejemplares similares

Cisplatin or Not in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis
por: Petrelli, Fausto, et al.
Publicado: (2013)

Lactobacillus Kefiri LKF01 (Kefibios(®)) for Prevention of Diarrhoea in Cancer Patients Treated with Chemotherapy: A Prospective Study
por: Ghidini, Michele, et al.
Publicado: (2021)

Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies
por: Petrelli, Fausto, et al.
Publicado: (2018)

Axillary dissection compared to sentinel node biopsy for the treatment of pathologically node-negative breast cancer: a meta-analysis of four randomized trials with long-term follow up
por: Petrelli, Fausto, et al.
Publicado: (2012)

Vitamin D3 and COVID-19 Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses
por: Petrelli, Fausto, et al.
Publicado: (2023)

Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade
por: Shen, Yanyun, et al.
Publicado: (2020)

COVID-19 and Lung Cancer Survival: An Updated Systematic Review and Meta-Analysis
por: Oldani, Simone, et al.
Publicado: (2022)

Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection
por: Parati, Maria Chiara, et al.
Publicado: (2022)

Factors associated with immune checkpoint inhibitor use among older adults with late-stage melanoma: A population-based study
por: Rai, Pragya, et al.
Publicado: (2021)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapy
por: Papaxoinis, George, et al.
Publicado: (2020)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

Resistance to Vemurafenib Can Be Reversible After Treatment Interruption: A Case Report of a Metastatic Melanoma Patient
por: Mackiewicz-Wysocka, Małgorzata, et al.
Publicado: (2014)

Metastatic malignant melanoma from anorectum presenting as an isolated breast tumor: A case report and literature review
por: Yi, Xiaokang, et al.
Publicado: (2022)

Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Petrelli, Fausto, et al.
Publicado: (2020)

Immunotherapy-related pneumonitis and bacterial pneumonia after the successful treatment of metastatic malignant melanoma with pembrolizumab: A case report
por: Ma, Qin, et al.
Publicado: (2021)

Using temporal heatmaps to identify worthwhile articles on immune checkpoint blockade for melanoma (ICBM) in Mainland China, Hong Kong, and Taiwan since 2000: A bibliometric analysis
por: Juang, Shiow-Jen, et al.
Publicado: (2023)

Immune-related adverse events with immune checkpoint inhibitors: Special reference to the effects on the lungs
por: Hirata, Aya, et al.
Publicado: (2021)

Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Pusceddu, Sara, et al.
Publicado: (2019)

The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis
por: Petrelli, Fausto, et al.
Publicado: (2023)

Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report
por: Liu, Shiwei, et al.
Publicado: (2022)

Three case reports: Temporal association between tyrosine-kinase inhibitor-induced hepatitis and immune checkpoint inhibitors in renal cell carcinoma
por: Carretero-González, Alberto, et al.
Publicado: (2019)

Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review
por: Gao, Loulu, et al.
Publicado: (2022)

Immune checkpoint inhibitors are effective in the treatment of Epstein-Barr virus-associated gastric cancer: A case report
por: An, Gaili, et al.
Publicado: (2023)

Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review
por: Pu, Dan, et al.
Publicado: (2020)

Immune checkpoint inhibitor sintilimab-induced lethal myocarditis overlapping with myasthenia gravis in thymoma patient: A case report
por: Wang, Chen, et al.
Publicado: (2023)

Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis
por: Xian, Feng, et al.
Publicado: (2022)

Changes of IL-6 And IFN-γ before and after the adverse events related to immune checkpoint inhibitors: A retrospective study
por: Zhang, Xu, et al.
Publicado: (2022)

A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019)

Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis
por: Zhang, Rui, et al.
Publicado: (2021)

Pathological pseudoprogression to anti-PD-1 inhibitor in metastatic periampullary carcinoma: Case report
por: Wang, Junhui, et al.
Publicado: (2023)

The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors
por: Liu, Na, et al.
Publicado: (2022)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Characteristics and prognosis of primary malignant melanoma of the esophagus
por: Chen, Hengchi, et al.
Publicado: (2020)

A new immune checkpoint-associated nine-gene signature for prognostic prediction of glioblastoma
por: Jin, Xiao, et al.
Publicado: (2023)

Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant)
por: Wu, Jia-Jun, et al.
Publicado: (2022)

Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report
por: Wen, Yan-Ping, et al.
Publicado: (2022)

Prognostic factors for postoperative survival in melanoma patients with bone metastasis
por: Wang, Yucheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bie0usip7lc8enm7vf7226a8dp